Axinn Obtains Dismissal of Monopolization and Attempted Monopolization Suit Against Rapid Aid, Ltd.
October 1, 2014
Axinn successfully obtained the dismissal with prejudice of a monopolization and attempted monopolization suit brought against Rapid Aid, Ltd., a Canadian manufacturer of hot-cold therapy products, by its rival Therapearl. Therapearl had alleged that Rapid Aid had filed a sham lawsuit against Therapearl in the Federal Court of Canada. Moving quickly, the Axinn team filed a motion to dismiss the complaint in its entirety within 10 days of being retained, arguing both that the antitrust claims were fatally flawed and that any action arising out of the parties’ Canadian dispute should be heard in Canada. In its decision, the U.S. District Court for the District of Maryland agreed with Rapid Aid that the plaintiff’s proposed market definition was facially insufficient and that its complaint also failed to allege either monopoly power or a dangerous probability of successful monopolization, and therefore dismissed the plaintiff’s Sherman Act claim with prejudice. It also dismissed the plaintiff’s request for a declaratory judgment and its state law claims, leaving Rapid Aid free to pursue its original Canadian claims without the overhang of U.S. litigation.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
DOJ's Antitrust Division Remains Interested in Your Private Litigation
Byline Articles
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust
